BACKGROUND
•  PASDAS, a validated composite index that assesses multiple facets 

of PsA, including joints, dactylitis, enthesitis, and quality of life 
(QoL),1 offers both a target and disease activity state assessment 
across important clinical domains with validated cutpoints2 (Figure 1)

•  PASDAS distinguishes treatment effect, performs better than 
traditional joint-only indices, and could be used as a treatment target 
in clinical trials and observational studies in PsA1,3

Figure 1. Disease Activity by PASDAS Score

Remission
PASDAS score ≤ 1.9

LDA
1.9 < PASDAS 

score < 3.2

MoDA
3.2 ≤ PASDAS score < 5.4

HDA
PASDAS score ≥ 5.4

4 6 820

HDA, high disease activity; LDA, low disease activity; MoDA, moderate disease activity; PASDAS, psoriatic arthritis 
disease activity score

•  Secukinumab is a fully human monoclonal antibody that selectively 
neutralizes interleukin-17A4

•  Secukinumab significantly improved multiple clinical domains 
of PsA, including signs and symptoms, physical function, QoL, 
and work productivity, over 104 weeks in the FUTURE 2 study 
(NCT01752634)5

METHODS
•  This post-hoc analysis assessed the ability of secukinumab to 

achieve and sustain LDA or remission by using PASDAS through  
104 weeks in the FUTURE 2 study

RESULTS
• Baseline disease characteristics were well balanced across all 

treatment groups (Table 1)

Table 1. Baseline Characteristics Across Groups6

Characteristic
Mean (SD), unless otherwise stated

Secukinumab 
300 mg s.c.

(N = 100)

Secukinumab 
150 mg s.c.

(N = 100)
Placebo
(N = 98)

Age, years 46.9 (12.6) 46.5 (11.7) 49.9 (12.5)
Female, n (%) 49 (49.0) 45 (45.0) 59 (60.2)
Time since first diagnosis of PsA  
in years 7.4 (7.5) 6.5 (8.2) 7.3 (7.8)

Anti–TNF-naïve, n (%) 67 (67.0) 63 (63.0) 63 (64.3)
Psoriasis ≥ 3% of BSA, n (%) 41 (41.0) 58 (58.0) 43 (43.9)
Physician Global VAS 55.0 (14.7) 56.7 (16.6) 55.0 (16.0)
Patient Global VAS 60.7 (18.9) 62.0 (19.5) 57.6 (19.8)
SF-36 PCS 36.9 (8.0) 36.2 (8.1) 37.4 (8.8)
Dactylitis count 3.6 (3.5) 4.5 (5.1) 2.7 (2.2)
Enthesitis count 2.8 (1.7) 3.2 (1.6) 3.1 (1.7)
TJC (78 joints) 20.2 (13.3) 24.1 (19.4) 23.4 (19.0)
SJC (76 joints) 11.2 (7.8) 11.9 (10.1) 12.1 (10.7)
PASDAS score 5.9 (0.9) 6.0 (1.0) 5.8 (1.0)

N, number of randomized patients. BSA, body surface area; PASDAS, psoriatic arthritis disease activity score;  
s.c., subcutaneous; SD, standard deviation; SF-36 PCS, Short Form-36 physical component summary; SJC, swollen joint 
count; TJC, total joint count; TNF, tumor necrosis factor; VAS, visual analog scale

Figure 4. Median Core Components of PASDAS Remission and LDA

Patient Global VASPhysician Global VAS

SJC 66

16 16 16

16

M
ed

ia
n 

(Q
1,

 Q
3)

 s
co

re

WeeksWeeks
LDA LDARemission

LDA Remission

Remission

LDA Remission
WeeksWeeks

M
ed

ia
n 

(Q
1,

 Q
3)

 s
co

re
M

ed
ia

n 
(Q

1,
 Q

3)
 s

co
re

M
ed

ia
n 

(Q
1,

 Q
3)

 s
co

re 40

30

20

10

0

0

2

4

6

8

0

2

4

6

8

0

5

10

15

20

16

16104 104

1616 104104

104

104 104

104

TJC 68

n 
= 

22
n 

= 
22

n 
= 

30
n 

= 
30

n 
= 

27
n 

= 
27

n 
= 

15
n 

= 
15

n 
= 

15
n 

= 
15

n 
= 

2
n 

= 
2

n 
= 

19

n 
= 

19

n 
= 

11

n 
= 

11

n 
= 

22
n 

= 
22

n 
= 

19
n 

= 
19

n 
= 

12
n 

= 
12

n 
= 

30
n 

= 
30

n 
= 

27
n 

= 
27

n 
= 

15
n 

= 
15

n 
= 

15
n 

= 
15

n 
= 

2
n 

= 
2

n 
= 

19
n 

= 
19

n 
= 

11
n 

= 
11

n 
= 

19
n 

= 
19

n 
= 

12
n 

= 
12

Secukinumab 300 mg s.c. Secukinumab 150 mg s.c. Placebo

16

1.0

0.8

0.6

0.4

0.2

0.0

65

60

55

50

45

40

WeeksWeeks
LDA LDARemission Remission

161616 104104 104 104

16WeeksWeeks
LDA LDARemission Remission

161616 104104 104 104

0.0

8

6

4

2

0

0.2

0.4

0.6

0.8

1.0

M
ed

ia
n 

(Q
1,

 Q
3)

 c
ou

nt
M

ed
ia

n 
(Q

1,
 Q

3)
 s

co
re

M
ed

ia
n 

(Q
1,

 Q
3)

 s
co

re
M

ed
ia

n 
(Q

1,
 Q

3)
 le

ve
l

Leeds Enthesitis Tender Dactylitis

SF-36 PCSC-Reactive Protein (mg/L)

n 
= 

22

n 
= 

22n 
= 

19

n 
= 

19n
 =

 3
0

n 
= 

30n
 =

 2
7

n 
= 

27

n 
= 

15 n
 =

 1
5

n 
= 

15

n 
= 

15

n 
= 

2

n 
= 

2

n 
= 

19 n
 =

 1
9

n 
= 

11 n
 =

 1
1

n 
= 

12

n 
= 

22

n 
= 

19

n 
= 

30

n 
= 

27

n 
= 

15

n 
= 

15

n 
= 

2

n 
= 

19
n 

= 
11

n 
= 

12

n 
= 

12

n 
= 

22

n 
= 

19

n 
= 

30

n 
= 

27

n 
= 

15

n 
= 

15

n 
= 

2

n 
= 

19

n 
= 

11

n 
= 

12

The median value is denoted by symbol in the figure while the upper and lower error bars represent third (Q3) and first 
(Q1) quartiles, respectively
n, number of patients in respective disease states at assessment
LDA, low disease activity; PASDAS, psoriatic arthritis disease activity score; Q, quartile; SF-36 PCS, Short Form-36 
physical component summary; SJC, swollen joint count; TJC, total joint count; VAS, visual analog scale

• TNF-naïve patients receiving secukinumab were more likely than 
TNF-IR patients to achieve PASDAS remission and LDA (Figure 5A)

• The proportion of patients achieving PASDAS remission and 
LDA with secukinumab was similar irrespective of time since first 
diagnosis of PsA (Figure 5B)

•  Patients achieving PASDAS remission and LDA with secukinumab 
were significantly more likely to report improvement in PsA QoL, 
Dermatology Life Quality Index, health assessment questionnaire 
disability index (HAQ-DI), and Functional Assessment of Chronic 
Illness Therapy-Fatigue scores than patients with HDA (Figure 6A)

• Patients achieving PASDAS remission and LDA with secukinumab 
reported significant improvements in measures of work productivity 
(Figure 6B)

Figure 5. (A) PASDAS Remission and LDA by Anti–TNF Exposure up to 
Week 104; (B) Effect of Disease Duration on PASDAS Remission and LDA

27.7
20.6

14.0 12.9 16.7 13.3

38.2
47.2

32.1

8.3

18.5
22.2

3.5 9.7
2.8

0

29.1 17.0

10.7

8.3

0

10

20

30

40

50

60

70

80

150 mg
(n = 63)

Placebo 
(n = 57)

stneitap fo noitropor
P

300 mg 
(n = 31)

150 mg
(n = 36)

Placebo 
(n = 30)

150 mg
(n = 24)

150 mg
(n = 53)

300 mg
(n = 55)

300 mg
(n = 28)

300 mg
(n = 65)

Week 16

Anti−TNF-IR

Week 104

Anti−TNF-IRAnti−TNF-naïveAnti−TNF-naïve

Secukinumab Secukinumab Secukinumab

LDA Remission

19.0 18.4
10.0

24.0 19.7 15.8

38.9
32.1 35.4 36.7

28.6
13.2

0

12.0 16.4
3.5

22.2

14.3
23.1 14.3

0

10

20

30

40

50

60

70

80

150 mg
(n = 38)

Placebo 
(n = 30)

stneitap fo noitropor
P

300 mg 
(n = 75)

150 mg
(n = 61)

Placebo 
(n = 57)

150 mg
(n = 49)

150 mg
(n = 28)

300 mg
(n = 18)

300 mg
(n = 65)

300 mg
(n = 21)

Week 16 Week 104

≤2 years >2 years ≤2 years >2 years

SecukinumabSecukinumabSecukinumab

LDA Remission

Data were reported using mutually exclusive categories at group level and as observed analysis. LDA: 1.9< PASDAS 
score <3.2; remission: PASDAS score ≤1.9. Secukinumab 300 and 150 mg data are reported (approved doses).  
n, number of patients in the treatment group with evaluation
IR, intolerance or inadequate response; LDA, low disease activity; PASDAS, psoriatic arthritis disease activity score;  
TNF, tumor necrosis factor

Figure 6. (A) PASDAS Remission and LDA and Patient-reported 
Outcomes; (B) PASDAS Remission and LDA and Work Productivity

HAQ-DI

-1.0

-0.8

-0.6

-0.4

-0.2

0.0

n 
= 

69

n 
= 

12
8

n 
= 

53

n 
= 

31

n 
= 

13

n 
= 

95

n 
= 

79

n 
= 

47

*

*

*

*

*

-4

0

4

8

12

16
FACIT-Fatigue

n 
= 

69

n 
= 

12
7

n 
= 

53

n 
= 

31

n 
= 

13

n 
= 

95
 

n 
= 

80

n 
= 

46

*

*

*
†

*

-12

-8

-4

0
PsA QoL

n 
= 

69 n 
= 

12
7

n 
= 

53

n 
= 

31

n 
= 

13

n 
= 

94

n 
= 

79

n 
= 

47

*

*
* *

*

Week 16 Week 104
-12

-8

-4

0
DLQI

n 
= 

61

n 
= 

11
6

n 
= 

51

n 
= 

29

n 
= 

10

n 
= 

84

n 
= 

73

n 
= 

45

*
*

*
‡

§

*

Week 16 Week 104L
S

 m
ea

n 
ch

an
ge

 ±
 S

E
LS

 m
ea

n 
ch

an
ge

 ±
 S

E

LS
 m

ea
n 

ch
an

ge
 ±

 S
E

LS
 m

ea
n 

ch
an

ge
 ±

 S
E

HDA RemissionMoDA LDA

-35
-30
-25
-20
-15
-10
-5
0
5

10

n 
 =

  2
8

n 
= 

63

n 
= 

35

n 
= 

16

n 
= 

3

n 
= 

42

n 
= 

40

n 
= 

26

*

Week 16 Week 104

Overall Work Impairment Due to Health

*

§

-20

-15

-10

-5

0

5

10

n 
= 

30 n
 =

 6
7

n 
= 

35

n 
= 

17

n 
= 

45

n 
= 

45

n 
= 

28

Week 16 Week 104

Work Time Missed Due to Health

4.4 0.14

-35
-30
-25
-20
-15
-10
-5
0
5

10

n 
= 

28

n 
= 

46

n 
= 

36

n 
= 

18

n 
= 

3

n 
= 

44

n 
= 

43

n 
= 

27

Week 16 Week 104

Impairment While Working Due to Health

*

*

‡

§

†

HDA RemissionMoDA LDA

LS
 m

ea
n 

ch
an

ge
 ±

 S
E

n 
 =

  3

Data from MMRM analysis are pooled across treatment arms. *P < 0.0001; †P < 0.001; §P < 0.01 and ‡P < 0.05 
versus HDA. n, number of patients with measurements at baseline and post-baseline visits. DLQI, Dermatology Life 
Quality Index; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy-Fatigue; HAQ-DI, health assessment 
questionnaire disability index; HDA, high disease activity; LDA, low disease activity; LS, least squares; MMRM, mixed-
effect model repeated measure; MoDA, moderate disease activity; PASDAS, psoriatic arthritis disease activity score;  
PsA, psoriatic arthritis; PsA QoL, PsA-specific quality of life; QoL, quality of life; SE, standard error

• The proportion of patients achieving PASDAS remission increased 
from Week 16 to Week 104 with both secukinumab 300 mg and 
secukinumab 150 mg (Figure 2)

Figure 2. PASDAS Remission and LDA Through Week 104

22.9 19.2
13.8

36.1 35.1

15.6
15.2

2.3

22.9
14.3

0

10

20

30

40

50

60

70

300 mg
(n = 96)

150 mg
(n = 99)

Placebo
(n = 87)

300 mg 
(n = 83)

150 mg
(n = 77)

stneitap fo noitropor
P

Secukinumab Secukinumab 

Week 16 Week 104

LDA Remission

Data were reported using mutually exclusive categories at group level and as observed analysis. LDA: 1.9< PASDAS 
score <3.2; remission: PASDAS score ≤1.9. Secukinumab 300 and 150 mg data are reported (approved doses).  
n, number of patients in the treatment group with evaluation.
LDA, low disease activity; PASDAS, psoriatic arthritis disease activity score

• The majority of patients receiving secukinumab sustained or 
improved their PASDAS disease activity state at Week 16 to Week 
52 and Week 104 (Figure 3)

Figure 3. Shift Analysis on PASDAS Disease Activity States 
From Week 16 to 52 or 104 

24.1

5.3 0.0

58.6

56.1

25.0

0.0

10.3
32.5

50.0

35.5

6.9 6.1
25.0

64.5

0

20

40

60

80

100

LDA
(n = 52)

MoDA
(n = 114)

HDA
(n = 58)

Remission
(n = 31)

Week 16 to Week 52 (N = 255)

PASDAS states at Week 16

19.6

1.0 4.2 0.0

54.9

49.5
22.9

10.0

15.7

39.0

41.7

40.0

9.8 10.5
31.3

50.0

0

20

40

60

80

100

Remission
(n = 30)

LDA
(n = 48)

MoDA
(n = 105)

HDA
(n = 51)

P
ro

po
rt

io
n 

of
 p

at
ie

nt
s 

at
 W

ee
k 

10
4

P
ro

po
rt

io
n 

of
 p

at
ie

nt
s 

at
 W

ee
k 

52

Week 16 to Week 104 (N = 234)

PASDAS states at Week 16

HDA RemissionMoDA LDA

Data pooled across treatment arms (secukinumab 300 and 150 mg). Data were reported using mutually exclusive 
categories at group level and as observed analysis. HDA: PASDAS score ≥5.4; MoDA: 3.2≤ PASDAS score <5.4;  
LDA: 1.9< PASDAS score <3.2; remission: PASDAS score ≤1.9. n, number of patients in each PASDAS state at Week 16; 
N, total number of patients with non-missing PASDAS score data at Weeks 16 and 52/104
HDA, high disease activity; LDA, low disease activity; MoDA, moderate disease activity;  
PASDAS, psoriatic arthritis disease activity score

• There were generally greater improvements in Physician Global 
Visual Analog Scale (VAS), Patient Global VAS, swollen joint count, 
and tender joint count in patients receiving secukinumab achieving 
PASDAS remission than LDA (Figure 4A)

• Severity of enthesitis and dactylitis was low in patients receiving 
secukinumab who achieved either PASDAS remission or LDA 
(Figure 4B)

 – Greater improvements in SF-36 PCS were observed in patients 
achieving PASDAS remission than LDA

A A

A

B

B

B

Secukinumab Achievement of Psoriatic Arthritis Disease Activity Score (PASDAS)-Related Remission: 
2-Year Results From a Phase 3 Study
LC Coates1, DD Gladman2, P Nash3, O FitzGerald4, A Kavanaugh5, L Rasouliyan6, L Pricop7, K Ding7, C Gaillez8, on behalf of the FUTURE 2 Study Group
1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; 2Toronto Western Hospital, Toronto, ON, Canada; 3University of Queensland, Brisbane, Australia; 4St Vincent’s University Hospital, Dublin, Ireland; 5UC San Diego School of Medicine,  
La Jolla, CA, USA; 6RTI Health Solutions, Barcelona, Spain; 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; 8Novartis Pharma AG, Basel, Switzerland

SUMMARY AND CONCLUSIONS
•  A high proportion of secukinumab-treated patients achieved 

PASDAS remission or LDA at Week 16 vs placebo, with sustained 
PASDAS through Week 104 

 –  In the overall population, in anti–TNF-naïve patients and 
irrespective of time since first PsA diagnosis (≤2 years vs  
>2 years)

•  PASDAS remission/LDA was associated with significantly greater 
improvement in health-related quality of life, HAQ-DI, fatigue, and 
work productivity

• PASDAS remission and LDA represent important states of 
disease activity in PsA with meaningful benefit on life impact from 
the patient perspective

Download document at the following URL:  
http://novartis.medicalcongressposters.com/Default.aspx?doc=11d0f

And via Text Message (SMS)

Text: Q11d0f 
To: 8NOVA (86682) US Only
+18324604729 North, Central and South Americas; Caribbean; China
+447860024038 UK, Europe & Russia
+46737494608 Sweden, Europe

Scan to download a  
reprint of this poster

ACKNOWLEDGEMENTS
The authors thank the patients and their families and all investigators and their staff for participation in the 
study. Oxford PharmaGenesis, Inc., Newtown, PA, USA, provided assistance with layout and printing the 
poster; this support was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ. The authors 
had full control of the contents of this poster.

This research was funded by Novartis Pharma AG, Basel, Switzerland.

Poster presented at: 13th Annual Winter Clinical Dermatology Conference, Maui, HI, USA;  
January 12–17, 2018.

Reprinted from the 2017 ACR/ARHP Annual Meeting held November 3‒8, 2017. The American College  
of Rheumatology does not guarantee, warrant, or endorse any commercial products or services.  
Reprinted by Novartis Pharmaceuticals Corporation.

REFERENCES
1. Helliwell PS and Kavanaugh A. Arth Care Res. 2014;66:749-56.

2. Helliwell PS, et al. Ann Rheum Dis. 2017;pii: annrheumdis-2016-211010.

3. Coates LC, et al. Ann Rheum Dis. 2017;76:1688–92.

4. Langley RG, et al. N Engl J Med. 2014;371:326–38. 

5. McInnes IB, et al. Rheumatology (Oxford). 2017;56(11):1993–2003. 

6. McInnes IB, et al. Lancet. 2015;386:1137–46.

DISCLOSURES
L Coates: Grant/research support from AbbVie, Janssen; consultant for AbbVie, BMS, Celgene, Pfizer, 
UCB, MSD, Boehringer Ingelheim, Novartis, Lilly, Janssen. DD Gladman: Grants and/or personal fees 
from Amgen, AbbVie, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, UCB. P Nash: Research grants 
and honoraria from Novartis, AbbVie, Roche, Pfizer, BMS, Janssen, Celgene. O Fitzgerald: Consultant for 
Bristol-Myers Squibb, Roche, Abbott Laboratories, Pfizer Inc, UCB Pharma Ltd; A Kavanaugh: Consultant 
for Novartis. L Rasouliyan: Consultant for Novartis through employment at RTI Health Solutions. L Pricop, 
K Ding, and C Gaillez: Shareholders and employees of Novartis.